|
Dec 26
|
Bristol Myers buying RayzeBio, FedEx buyback: Trending tickers
|
|
Dec 24
|
15 Undervalued Defensive Stocks For 2024
|
|
Dec 22
|
S&P 500 Gains and Losses Today: Nike Warns of Soft Sales and Plans Spending Cuts
|
|
Dec 22
|
Bristol's $14 Billion Takeover Of Karuna Pulled A Bevy Of Stocks Higher
|
|
Dec 22
|
Rocket Lab, Coinbase, Bristol Myers-Karuna deal: Trending tickers
|
|
Dec 22
|
Bristol Myers Squibb acquires Karuna Therapeutics for $14 billion, boosting neuroscience portfolio
|
|
Dec 22
|
Midday Movers: Karuna Jumps on Deal With Bristol Myers Squibb, Nike Falls on Sales Outlook
|
|
Dec 22
|
Bristol Myers Squibb Boosts Its Neuroscience Reach With $14 Billion Karuna Deal
|
|
Dec 22
|
Bristol Myers to Buy Karuna Therapeutics in $14 Billion Pharma Deal
|
|
Dec 22
|
Karuna Therapeutics soars after $14 billion takeover by Bristol Myers
|
|
Dec 22
|
Bristol Myers (BMY) to Buy Karuna Therapeutics for $14B
|
|
Dec 22
|
Bristol Myers acquiring Karuna Therapeutics in $14B deal
|
|
Dec 22
|
3 Attractive Healthcare Dividend Stocks for 2024
|
|
Dec 22
|
5 Things to Know Before The Stock Market Opens
|
|
Dec 22
|
Bristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna Therapeutics
|
|
Dec 22
|
Bristol Myers Squibb to Present at J.P. Morgan’s 42nd Annual Healthcare Conference
|
|
Dec 22
|
Bristol Myers to buy schizophrenia drugmaker Karuna Therapeutics for $14 billion
|
|
Dec 22
|
Bristol Myers to Buy Karuna Therapeutics for $14 Billion
|
|
Dec 22
|
Bristol Myers to acquire brain drug developer Karuna for $14B
|
|
Dec 21
|
Bristol Myers Squibb (BMY) Rises But Trails Market: What Investors Should Know
|